Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Metastatic Breast Cancer
Related studies linked through entity extraction aliases.
Evaluation of the Acceptability, Appropriateness, and Feasibility/Usability of a Metastatic Breast-cancer Specific Prognostic Calculator Among Clinicians
- Status
- RECRUITING
- Phase
- N/A
Circulating Tumor DNA (ctDNA)-Guided Late-Line Treatment in Patients With Late-Stage Breast Cancer
- Status
- COMPLETED
- Phase
- N/A
Onvansertib + Paclitaxel In TNBC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor
- Status
- COMPLETED
- Phase
- N/A
Comprehensive Outcomes for After Cancer Health
- Status
- RECRUITING
- Phase
- NA
Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab
- Status
- UNKNOWN
- Phase
- PHASE3
Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer.
- Status
- COMPLETED
- Phase
- PHASE2
Preoperative Radiotherapy and Systemic Therapy Following Surgery in 'de Novo' Metastatic Breast Cancer
- Status
- RECRUITING
- Phase
- N/A
A Study of RC48-ADC for the Treatment of HER2-expression Metastatic Breast Cancer With Abnormal Activation of PAM Pathway
- Status
- UNKNOWN
- Phase
- PHASE2
Prognostic Impact of the Neutrophil/Lymphocyte Ratio (NLR) in the Treatment of First-line Metastatic or Locally Advanced Breast Cancer Treated With CDK4/6 Inhibitor.
- Status
- COMPLETED
- Phase
- NA
Eribulin as a Second-line Treatment in Triple-negative Advanced Breast Cancer
- Status
- UNKNOWN
- Phase
- N/A
Classified Treatment Strategy for De-novo Metastatic Breast Cancer After Systemic Adjuvant Therapy
- Status
- NOT_YET_RECRUITING
- Phase
- NA
A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Immunogenicity of Test Pertuzumab (ZRC-3277, Cadila Healthcare Ltd.,)
- Status
- COMPLETED
- Phase
- PHASE3
Atezolizumab Plus CArboplatin Plus Nab-paclitaxel
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Radiotherapy in Combo With Chemo and Immunotherapy in Patients With PD-L1 Positive Metastatic TNBC
- Status
- WITHDRAWN
- Phase
- PHASE2
Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
Real-World Data of Clinicopathological Characteristics and Management of Breast Cancer Patients According to HER2 Status
- Status
- COMPLETED
- Phase
- N/A
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1